Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 6;14(1):5508.
doi: 10.1038/s41598-024-55989-4.

Neutralizing immunity against coronaviruses in Tanzanian health care workers

Collaborators, Affiliations

Neutralizing immunity against coronaviruses in Tanzanian health care workers

Godfrey Barabona et al. Sci Rep. .

Abstract

The ongoing vaccination efforts and exposure to endemic and emerging coronaviruses can shape the population's immunity against this group of viruses. In this study, we investigated neutralizing immunity against endemic and emerging coronaviruses in 200 Tanzanian frontline healthcare workers (HCWs). Despite low vaccination rates (19.5%), we found a high SARS-CoV-2 seroprevalence (94.0%), indicating high exposure in these HCWs. Next, we determined the neutralization capacity of antisera against human coronavirus NL63, and 229E, SARS-CoV-1, MERS-CoV and SARS-CoV-2 (including Omicron subvariants: BA.1, BQ.1.1 and XBB.1.5) using pseudovirus neutralization assay. We observed a broad range of neutralizing activity in HCWs, but no neutralization activity detected against MERS-CoV. We also observed a strong correlation between neutralizing antibody titers for SARS-CoV-2 and SARS-CoV-1, but not between other coronaviruses. Cross-neutralization titers against the newer Omicron subvariants, BQ.1.1 and XBB.1.5, was significantly reduced compared to BA.1 and BA.2 subvariants. On the other hand, the exposed vaccinated HCWs showed relatively higher median cross-neutralization titers against both the newer Omicron subvariants and SARS-CoV-1, but did not reach statistical significance. In summary, our findings suggest a broad range of neutralizing potency against coronaviruses in Tanzanian HCWs with detectable neutralizing immunity against SARS-CoV-1 resulting from SARS-CoV-2 exposure.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Neutralization capacity of plasma (n = 186) form HCWs against coronaviruses spikes pseudotyped viruses. (a) Neutralisation profile of plasma against SARS-CoV-2 wildtype, SARS-CoV-1, MERS-CoV, HCoV-229E, and HCoV-NL63. (b) Comparison of neutralization titers between SARS-CoV-2 exposed-vaccinated (indicated by solid circles symbols) and exposed-unvaccinated (open diamond symbols), and (c) between SARS-CoV-2 seropositive (circle symbols) and seronegative groups (triangle symbols). The horizontal dotted line indicates the lowest limit of dilution tested (1:40). Statistical significance was determined using the Mann–Whitney-U rank test and P value < 0.05 was considered significant, (d) Spearman's correlation between neutralization titers for coronaviruses and the total anti-SARS-CoV-2 RBD binding antibodies quantified by ELISA. WT wild-type, NT neutralization titer.
Figure 2
Figure 2
Cross-neutralization of HCWs' plasma against newer omicron subvariants. (a) Matched paired analysis comparing neutralization titers for HCWs' plasma (n = 68) against wild-type SARS-CoV-2 and Omicron subvariants. “a” median NT50, “b” percentage of samples with NT50 > 40. Statistical significance was determined using the Wilcoxon test (****: P < 0.0001). (b) Comparison of neutralization titers across Omicron subvariants between SARS-CoV-2-exposed-vaccinated and SARS-CoV-2-exposed-unvaccinated HCWs. Statistical significance was determined using the Mann–Whitney-U rank test. In (a,b), the horizontal dotted line indicates the lowest limit of dilution tested (1:40).

References

    1. Ng KW, Faulkner N, Wrobel AG, Gamblin SJ, Kassiotis G. Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel. Semin. Immunol. 2021;55:101507. doi: 10.1016/j.smim.2021.101507. - DOI - PMC - PubMed
    1. Borrega, R. et al. Cross-reactive antibodies to SARS-COV-2 and MERS-COV in pre-covid-19 blood samples from sierra leoneans. Viruses13, 2325 (2021). - PMC - PubMed
    1. Grobben, M. et al. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. Elife10, e70330 (2021). - PMC - PubMed
    1. Tso FY, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int. J. Infect. Dis. 2021;102:577–583. doi: 10.1016/j.ijid.2020.10.104. - DOI - PMC - PubMed
    1. Pedersen J, et al. Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic. Sci. Rep. 2022;12:1–7. doi: 10.1038/s41598-022-17241-9. - DOI - PMC - PubMed